Literature DB >> 24025658

Medicare Part D plan generosity and medication use among dual-eligible nursing home residents.

Haiden A Huskamp1, David G Stevenson, A James O'Malley, Stacie B Dusetzina, Susan L Mitchell, Barbara J Zarowitz, Michael E Chernew, Joseph P Newhouse.   

Abstract

BACKGROUND: In 2006, dual-eligible nursing home residents were randomly assigned to a Medicare Part D prescription drug plan (PDP). Subsequently, residents not enrolled in qualified plans at the start of the next year were rerandomized. PDPs vary in generosity through differences in medication coverage and utilization management. Therefore, residents' assigned plans may be relatively more or less generous for their particular drugs. The impact of generosity on residents' medication use and health outcomes is unknown.
METHODS: Using data from 2005 to 2008, we estimated logistic regression models of the impact of coverage and utilization management on the risk for medication changes and gaps in use, hospitalizations, and death among elderly nursing home residents using 1 of 6 selected drug classes, adjusting for patient characteristics.
RESULTS: Few current medication users faced noncoverage of their drug (0.4% to 8.7%) or prior authorization or step therapy requirements if the drug was covered (1.1% to 37.4%). After adjusting for individual-level covariates, residents with noncovered drugs were more likely than residents with covered drugs to change medications in most classes studied (eg, for 2006 angiotensin receptor blocker users, the adjusted average probability of medication change was 0.35 when uncovered vs. 0.11 when covered). Those subjected to prior authorization or step therapy were more likely to change in a subset of classes. There were no statistically significant differences in the rates of hospitalization or death after correcting for multiple comparisons.
CONCLUSIONS: The Part D benefit's special protections for nursing home residents may have ameliorated the health impact of coverage limits on this frail elderly population.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24025658      PMCID: PMC3773176          DOI: 10.1097/MLR.0b013e31829fafdc

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   2.983


  30 in total

1.  Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors.

Authors:  Michael A Fischer; Sebastian Schneeweiss; Jerry Avorn; Daniel H Solomon
Journal:  N Engl J Med       Date:  2004-11-18       Impact factor: 91.245

2.  Differential effect of early or late implementation of prior authorization policies on the use of Cox II inhibitors.

Authors:  Elizabeth E Roughead; Fang Zhang; Dennis Ross-Degnan; Stephen Soumerai
Journal:  Med Care       Date:  2006-04       Impact factor: 2.983

Review 3.  Drug use in the nursing home.

Authors:  J Avorn; J H Gurwitz
Journal:  Ann Intern Med       Date:  1995-08-01       Impact factor: 25.391

4.  The impact of Medicare Part D on hospitalization rates.

Authors:  Christopher C Afendulis; Yulei He; Alan M Zaslavsky; Michael E Chernew
Journal:  Health Serv Res       Date:  2011-02-09       Impact factor: 3.402

5.  Impact of prior authorization on the use and costs of lipid-lowering medications among Michigan and Indiana dual enrollees in Medicaid and Medicare: results of a longitudinal, population-based study.

Authors:  Christine Y Lu; Michael R Law; Stephen B Soumerai; Amy Johnson Graves; Robert F LeCates; Fang Zhang; Dennis Ross-Degnan; Alyce S Adams
Journal:  Clin Ther       Date:  2011-01       Impact factor: 3.393

6.  Use of atypical antipsychotic drugs for schizophrenia in Maine Medicaid following a policy change.

Authors:  Stephen B Soumerai; Fang Zhang; Dennis Ross-Degnan; Daniel E Ball; Robert F LeCates; Michael R Law; Tom E Hughes; Daniel Chapman; Alyce S Adams
Journal:  Health Aff (Millwood)       Date:  2008-04-01       Impact factor: 6.301

7.  Adverse events related to drugs and drug withdrawal in nursing home residents.

Authors:  M B Gerety; J E Cornell; D T Plichta; M Eimer
Journal:  J Am Geriatr Soc       Date:  1993-12       Impact factor: 5.562

8.  Nursing home residents and enrollment in Medicare Part D.

Authors:  Becky A Briesacher; Stephen B Soumerai; Terry S Field; Hassan Fouayzi; Jerry H Gurwitz
Journal:  J Am Geriatr Soc       Date:  2009-08-21       Impact factor: 5.562

9.  The effect of Medicare Part D on drug and medical spending.

Authors:  Yuting Zhang; Julie M Donohue; Judith R Lave; Gerald O'Donnell; Joseph P Newhouse
Journal:  N Engl J Med       Date:  2009-07-02       Impact factor: 91.245

10.  The effect of the Medicare Part D prescription benefit on drug utilization and expenditures.

Authors:  Wesley Yin; Anirban Basu; James X Zhang; Atonu Rabbani; David O Meltzer; G Caleb Alexander
Journal:  Ann Intern Med       Date:  2008-01-07       Impact factor: 25.391

View more
  4 in total

1.  Adequacy of Prescription Drug Coverage in Long-term Care.

Authors:  Becky Briesacher; Brianne Oliveri-Mui; Bhavika Chhabra; Benjamin Koethe
Journal:  Med Care       Date:  2020-05       Impact factor: 2.983

2.  Effect of Part D coverage restrictions for antidepressants, antipsychotics, and cholinesterase inhibitors on related nursing home resident outcomes.

Authors:  David G Stevenson; A James O'Malley; Stacie B Dusetzina; Susan L Mitchell; Barbara J Zarowitz; Michael E Chernew; Joseph P Newhouse; Haiden A Huskamp
Journal:  J Am Geriatr Soc       Date:  2014-08-14       Impact factor: 5.562

3.  Association of Race and Poverty With Mortality Among Nursing Home Residents on Maintenance Dialysis.

Authors:  Robert Nee; John S Thurlow; Keith C Norris; Christina Yuan; Maura A Watson; Lawrence Y Agodoa; Kevin C Abbott
Journal:  J Am Med Dir Assoc       Date:  2019-03-28       Impact factor: 7.802

4.  Frequency and Predictors of Analgesic Prescribing in U.S. Nursing Home Residents with Persistent Pain.

Authors:  Kevin M Fain; G Caleb Alexander; David D Dore; Jodi B Segal; Andrew R Zullo; Carlos Castillo-Salgado
Journal:  J Am Geriatr Soc       Date:  2016-11-07       Impact factor: 7.538

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.